Yukihiro Chino
Saitama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
The preclinical profiles and the clinical efficacy and safety of vornorexant (Vorzzz® tablets), a new orexin receptor antagonist
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: May 06, 2026
Effects of Vornorexant, a Dual Orexin Receptor Antagonist, on Bladder Function in Rats and Nocturnal Voiding Frequency in Patients With Insomnia.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: December 16, 2025
Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia.
Journal: Pharmacology research & perspectives
Published: November 07, 2025
Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant.
Journal: The international journal of neuropsychopharmacology
Published: July 09, 2025
Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis.
Journal: Journal of clinical pharmacology
Published: July 19, 2023
Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials.
Journal: Arthritis research & therapy
Published: November 14, 2022
Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.
Journal: Journal of clinical pharmacology
Published: July 06, 2021
Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: June 28, 2016
In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: June 22, 2016
Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: October 23, 2015
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
Journal: Biopharmaceutics & drug disposition
Published: January 10, 2014
Showing 1-11 of 11
Last Updated: 09/26/2026